Knee Steroid Injections: What the Triamcinolone-versus-Saline Trial Found on Cartilage and Pain

Intra-articular corticosteroid injection is used to reduce pain during a flare of knee osteoarthritis. A single injection can help some people for days or weeks. That short-term question is different from giving an injection on a fixed schedule every three months for years.

A 2017 randomized trial tested the repeated-schedule question. One hundred forty adults with symptomatic knee osteoarthritis and ultrasound evidence of synovitis received 40 milligrams of triamcinolone acetonide or saline into the knee every twelve weeks for two years. MRI showed greater cartilage loss with triamcinolone, while pain measured at scheduled visits did not differ significantly.

The clinical question was repeated maintenance#

The McAlindon trial enrolled participants with Kellgren-Lawrence grade 2 or 3 knee osteoarthritis. They had pain and ultrasound features consistent with synovitis, and randomization assigned the active or saline injection every twelve weeks regardless of whether a participant requested another injection because pain had returned.

This design answers whether suppressing synovitis on a regular schedule preserves cartilage and improves symptoms over two years, but it does not directly answer whether one injection helps a person with an acute effusion before a major event or during rehabilitation.

Blinding was a strength. Saline injection controlled for the procedure, attention, expectation, joint aspiration, and natural symptom variation. MRI provided a sensitive structural outcome.

The cartilage result#

The primary structural outcome was change in cartilage thickness in the index compartment. Mean thickness decreased by 0.21 millimeters in the triamcinolone group and 0.10 millimeters in saline, and the between-group difference was minus 0.11 millimeters, with a 95 percent confidence interval from minus 0.20 to minus 0.03.

This was statistically significant and opposite the hypothesis that reducing synovitis might protect cartilage, and the result raises concern that repeated corticosteroid injection can accelerate structural loss, at least under the studied schedule and population.

MRI thickness is a surrogate structural measure. The minimal difference that reliably changes pain, function, or time to joint replacement is not firmly established. That uncertainty does not erase the signal; it limits how directly the 0.11-millimeter difference translates into patient experience.

The pain result#

Pain decreased in both groups. The between-group difference over two years was not statistically significant: the paper reported changes of minus 1.2 in the triamcinolone group and minus 1.9 with saline on its pain scale, with a between-group estimate that did not favor triamcinolone.

Assessments occurred at three-month intervals, near the time the next injection was due. Corticosteroid benefit is often greatest during the first weeks. If pain improved after injection and then returned before the next visit, the study schedule could miss that transient effect.

So the trial shows no sustained pain advantage at repeated quarterly assessments. It says much less about pain on day seven or week three. A claim that “steroid injections never help pain” goes beyond the design.

Why saline is not an empty comparison#

Injecting saline can have a contextual effect. Needle placement, aspiration of joint fluid, expectation, contact with clinicians, and regression toward the mean can improve reported symptoms, and saline itself may have local effects, although it is used as a procedural control.

Osteoarthritis pain fluctuates. People seek an injection when pain is high, and some improvement would come anyway without an active drug; randomization controls that pattern, but it means the comparison is procedure versus procedure plus steroid, not injection versus no contact at all. So what the trial measures is the extra benefit triamcinolone bought on top of a saline injection, under this protocol.

Who was represented#

The mean age was 58, and 54 percent were women. Participants had moderate radiographic disease and sonographic synovitis features. People with end-stage bone-on-bone disease, very early symptoms, inflammatory arthritis, or many major comorbidities may respond differently.

Eighty-five percent completed the trial. Missing data and discontinuation were handled in the analysis, but loss to follow-up can still affect precision; one hundred forty participants is substantial for an MRI trial and modest for uncommon safety events. The study used one formulation and dose. Other corticosteroids, extended-release formulations, image guidance, injection intervals, or aspiration strategies cannot be assumed equivalent.

How this fits other evidence#

The Cochrane review found that intra-articular corticosteroids may improve pain and function in the short term, but study quality, heterogeneity, and small-study effects reduced confidence. Benefits diminished over time.

The American College of Rheumatology guideline strongly recommends intra-articular glucocorticoid injection for knee or hip osteoarthritis as a treatment option, while recognizing short-term efficacy. The AAOS guideline states that injections could provide short-term relief.

These recommendations and the cartilage trial can coexist. Guidelines consider temporary symptom relief, alternatives, feasibility, and patient preference. The trial warns against regular long-term scheduling and adds structural harm to the tradeoff.

Structural concerns beyond this trial#

Case series and imaging observations have described accelerated osteoarthritis, subchondral insufficiency fracture, osteonecrosis, and rapid joint destruction after injections in some patients, but causation is difficult because people selected for injection may already have severe or rapidly progressing disease.

The Radiology expert panel reviewed these concerns and the uncertainty around screening imaging and informed consent. A sudden increase in pain out of proportion to prior disease may warrant evaluation for insufficiency fracture or another diagnosis before injection. Rare events cannot be estimated well from a 140-person trial. Their possibility supports careful diagnosis and avoiding a reflexive injection without reassessment.

Infection and procedural risk#

Septic arthritis after injection is rare but serious. Sterile technique, skin assessment, and avoiding injection through cellulitis are essential. If you develop fever, escalating pain, marked swelling, or you cannot move the joint after an injection, get assessed urgently.

Bleeding risk depends on anticoagulant, dose, procedure, and patient factors; many joint injections can be performed safely without interrupting anticoagulation, but the plan should follow current procedural guidance and the person's thrombotic risk.

A short post-injection flare can occur. Local skin atrophy or pigment change is possible. Repeated injections may increase cumulative local risk.

Glucose and systemic effects#

Even a joint injection can produce systemic corticosteroid absorption. Blood glucose may rise for several days, particularly in diabetes. The trial found a small between-group HbA1c difference, but HbA1c is too averaged to show short peaks.

The triamcinolone labeling resource lists systemic corticosteroid precautions. If you use insulin or a medicine that can cause hypoglycemia, what you need is an individualized monitoring and adjustment plan, not a blanket rule against all injections. Transient facial flushing, sleep disturbance, mood change, or blood-pressure effects can occur. Multiple joints or frequent dosing increases systemic burden.

Timing before joint replacement#

Observational studies suggest possible increased prosthetic-joint infection risk when corticosteroid injection occurs close to arthroplasty, often within three months. Confounding remains, and thresholds vary among surgeons and studies.

If you are considering a knee replacement, tell the orthopedic team the exact injection date, the drug, and the joint. That one piece of coordination avoids an injection that delays your surgery or complicates the risk planning around it.

Core treatments remain core#

Exercise, strength, aerobic activity, and neuromuscular training are central treatments for knee osteoarthritis. Scale the activity to your symptoms and function rather than dropping it, and weight loss can reduce knee load and improve symptoms for people with overweight or obesity who want that approach.

Topical nonsteroidal anti-inflammatory drugs can help with less systemic absorption than oral forms. Oral medicines require review of kidney, gastrointestinal, cardiovascular, and bleeding risk. Bracing, cane use, physical therapy, sleep, and pain-coping strategies may add benefit.

An injection should open a window for function or rehabilitation, not replace the plan. Name the target before the needle goes in: walking to the end of your street, sleeping through the night, getting through physical therapy, or riding out a flare.

A decision framework for injection#

Confirm that pain arises from the knee joint and that infection, crystal arthritis, fracture, referred hip pain, radiculopathy, or another process is not being missed. Review severity, effusion, prior response, diabetes, anticoagulation, immune status, skin, and surgical plans.

Discuss the expected duration and the uncertainty. One injection that worked does not guarantee the next one will. Track your pain and function at one to six weeks rather than waiting until the three-month mark. If the benefit was absent or brief, repeating on schedule is hard to justify.

Avoid a standing quarterly schedule without reassessing need. Use the lowest practical frequency, inside a plan that also carries the core treatments. The 2017 trial's warning is most directly about fixed repeated use.

Reading the result without absolutes#

The evidence does not support two common extremes. “The injection is harmless because it stays in the knee” ignores cartilage and systemic concerns. “The trial proved steroid shots never work” ignores the timing of pain measurement and other short-term evidence.

A faithful conclusion is narrower: repeated 40-milligram triamcinolone every twelve weeks for two years caused greater MRI cartilage loss and no sustained pain advantage over saline in this trial. A selective injection may still offer temporary relief, but the benefit should have a purpose and a stop rule.

References#

1. Triamcinolone versus saline randomized trial
2. ACR osteoarthritis guideline
3. AAOS knee osteoarthritis guideline
4. Cochrane corticosteroid injection review
5. Radiology expert panel
6. Triamcinolone labeling